Can prednisolone be continued for a COPD exacerbation despite tingling and drowsiness as adverse reactions?

Can Prednisolone Be Continued for COPD Exacerbation Despite Tingling and Drowsiness?

Yes, prednisolone should generally be continued for the COPD exacerbation, as tingling and drowsiness are not typical serious adverse effects that warrant discontinuation, and the benefits of systemic corticosteroids in reducing treatment failure and improving outcomes likely outweigh these mild symptoms.

Clinical Reasoning

The symptoms described—tingling and drowsiness—are not among the well-documented serious adverse effects of prednisolone that would necessitate immediate discontinuation. The FDA label and clinical guidelines identify the primary concerns with systemic corticosteroids as hyperglycemia, infections, psychiatric disturbances, and gastrointestinal complications 1. Neither tingling nor drowsiness appear as major adverse reactions in the drug labeling 1.

Evidence Supporting Continuation

Benefits in COPD Exacerbations

Systemic corticosteroids remain a cornerstone of COPD exacerbation management 2, 3. The ERS/ATS guidelines recommend a short course (≤14 days) of oral corticosteroids for ambulatory patients with COPD exacerbations, with the 2014 GOLD document specifically recommending 30-40 mg prednisone daily for 5 days 2.

The benefits include:

• Reduced treatment failure rates (composite of death, no resolution, or deterioration)
• Improved lung function (mean FEV1 increase of 0.16 L)
• Trend toward fewer hospitalizations (7.9% vs 17% without steroids)
• Shorter recovery time and reduced risk of early relapse 2

Recent high-quality evidence from the STARR2 trial (2024) demonstrated that blood eosinophil-guided prednisolone therapy was non-inferior to standard care, with treatment failures occurring in only 19% of the biomarker-guided group versus 32% in standard treatment 4.

Known Adverse Effects to Monitor

The documented adverse effects that clinicians should actively monitor include 2, 1:

• Hyperglycemia (most common—occurs in 33-50% of patients) 5, 6
• Psychiatric symptoms (anxiety, depression, insomnia)
• Infections
• Gastrointestinal effects
• Hypertension
• Seizures (rare)

Evaluating the Reported Symptoms

Tingling

Tingling (paresthesias) is not a standard prednisolone adverse effect listed in FDA labeling 1. Consider alternative explanations:

• Hyperglycemia-related neuropathy (check blood glucose)
• Electrolyte disturbances, particularly hypokalemia (prednisolone can cause potassium depletion, especially with concurrent diuretics) 1
• Unrelated neurological issues
• Anxiety manifestation (which IS a known steroid effect)

Drowsiness

Drowsiness is paradoxical, as insomnia is the typical neuropsychiatric effect of corticosteroids 2, 1. This symptom warrants investigation for:

• Worsening hypercapnia from the COPD exacerbation itself
• Concurrent medication effects
• Infection or sepsis
• Metabolic derangements

Practical Management Algorithm

1. Assess severity of COPD exacerbation:

• If significant breathlessness interfering with daily activities → continue prednisolone 2
• The risk of treatment failure without steroids (42% vs 27% with treatment) outweighs mild side effects 2

2. Investigate the symptoms:

• Check blood glucose immediately (hyperglycemia occurs in ~50% of patients) 5, 6
• Check electrolytes, particularly potassium 1
• Assess for worsening respiratory status (drowsiness may indicate CO2 retention)
• Review all concurrent medications for interactions

3. Optimize the steroid regimen:

• Use the shortest effective duration (5 days is as effective as 14 days) 7
• Standard dose: 30-40 mg daily 2
• Consider checking blood eosinophil count if available—patients with eosinophils ≥2% have better response (11% treatment failure vs 66% with placebo) 2, 4

4. Address specific symptoms:

• If hyperglycemia present → adjust diabetic medications or initiate insulin 1
• If hypokalemia → supplement potassium 1
• If drowsiness persists → evaluate for hypercapnia with arterial blood gas

Critical Caveats

• Do not abruptly discontinue if the patient has been on long-term corticosteroid therapy—taper gradually 1
• The cumulative lifetime dose threshold of ≥1000 mg prednisolone-equivalent is associated with adverse health effects; 26% of COPD patients reach this threshold in just 12 months 8
• Patients requiring ventilatory support may not benefit from steroids and face increased hyperglycemia risk (49.5% vs 33%) 5
• Oral administration is as effective as IV in most hospitalized patients 9

When to Reconsider Continuation

Discontinuation would be warranted for:

• Severe hyperglycemia unresponsive to treatment
• Acute psychiatric crisis
• Severe infection or sepsis
• Documented allergic reaction
• Seizures

The mild symptoms of tingling and drowsiness do not meet criteria for discontinuation, particularly when weighed against the substantial risk of treatment failure without corticosteroids in a COPD exacerbation.